Intarcia's ITCA 650 heading for 3Q submission

Intarcia Therapeutics Inc. (Boston, Mass.) said ITCA 650 met the primary endpoint in the Phase III FREEDOM-CVO cardiovascular outcomes study to treat Type II diabetes.

Read the full 257 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE